Abstract
The efficacy of antiplatelet therapy for the secondary prevention of cardiovascular disease after an ischemic event is well established. However, the role for antiplatelet therapy for the primary prevention of cardiovascular disease is more complex because of the interplay of efficacy vs safety in individuals without established cardiovascular disease who have a relatively low, but linear trajectory of cardiovascular risk. Several large randomized trials have investigated the efficacy and safety of antiplatelet therapy (primarily aspirin) for patients without established cardiovascular disease. The pharmacological profile of the most commonly used primary prevention antiplatelet agent, aspirin, has been delineated by randomized clinical trials and showcased in practice guidelines for reducing cardiovascular risk. For this indication, aspirin has been consistently shown to reduce the risk of non-fatal myocardial infarction with little impact on cardiovascular death, but with a consistent increased risk of bleeding. These divergent results have contributed to differences in the recommendations from international practice guidelines and highlight controversy at the forefront of considerations for anti-platelet therapy for primary prevention. However, further studies in specific sub-groups of patients without established cardiovascular disease such as those with Diabetes Mellitus, chronic kidney disease, or the elderly may clarify which patient groups will benefit the most from aspirin treatment for the primary prevention of a cardiovascular event.
Keywords: Aspirin, primary prevention, cardiovascular disease, antiplatelet therapy, review, cardiovascular mortality.
Current Pharmaceutical Design
Title:The Role of Antiplatelet Therapy in Primary Prevention. A Review
Volume: 23 Issue: 9
Author(s): Lauge Ostergaard*, Emil L. Fosbol and Matthew T. Roe
Affiliation:
- Lauge Østergaard, Blegdamsvej 9, 2100 Copenhagen,Denmark
Keywords: Aspirin, primary prevention, cardiovascular disease, antiplatelet therapy, review, cardiovascular mortality.
Abstract: The efficacy of antiplatelet therapy for the secondary prevention of cardiovascular disease after an ischemic event is well established. However, the role for antiplatelet therapy for the primary prevention of cardiovascular disease is more complex because of the interplay of efficacy vs safety in individuals without established cardiovascular disease who have a relatively low, but linear trajectory of cardiovascular risk. Several large randomized trials have investigated the efficacy and safety of antiplatelet therapy (primarily aspirin) for patients without established cardiovascular disease. The pharmacological profile of the most commonly used primary prevention antiplatelet agent, aspirin, has been delineated by randomized clinical trials and showcased in practice guidelines for reducing cardiovascular risk. For this indication, aspirin has been consistently shown to reduce the risk of non-fatal myocardial infarction with little impact on cardiovascular death, but with a consistent increased risk of bleeding. These divergent results have contributed to differences in the recommendations from international practice guidelines and highlight controversy at the forefront of considerations for anti-platelet therapy for primary prevention. However, further studies in specific sub-groups of patients without established cardiovascular disease such as those with Diabetes Mellitus, chronic kidney disease, or the elderly may clarify which patient groups will benefit the most from aspirin treatment for the primary prevention of a cardiovascular event.
Export Options
About this article
Cite this article as:
Ostergaard Lauge*, Fosbol L. Emil and Roe T. Matthew, The Role of Antiplatelet Therapy in Primary Prevention. A Review, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161205115540
DOI https://dx.doi.org/10.2174/1381612822666161205115540 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Efforts to Develop Imaging Methods and β -Cell-Specific Contrast Agents for Non-Invasive in vivo Assessment of β-Cell Mass
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Current Vascular Pharmacology Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening Smooth Muscle Cell Pathophysiology and Advanced Glycation End Products (AGEs)
Current Drug Targets Impact of Postprandial Remnant Lipoproteins on Coronary Artery Disease
Vascular Disease Prevention (Discontinued) Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Neutral Actions of Raltegravir on Adipogenesis, Glucose Metabolism and Lipolysis in 3T3-L1 Adipocytes
Current HIV Research Effects of Melatonin on Peripheral Nerve Regeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Chemical and Physical Aspects of the Edible Fractions and Seeds of Jamelao (Syzygium cumini, L. Skeels)
The Natural Products Journal Phytochemical Composition, Biological Activities and Processing Method of Genus <i>Anisophyllea</i>: A Review
The Natural Products Journal Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Modulation of Cardiac Metabolism During Myocardial Ischemia
Current Pharmaceutical Design Meet Our Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Basis of Renal Mass in Rat Models
Current Hypertension Reviews Exosome Limitations in the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Protective Effect of Notoginsenoside R1 on an APP/PS1 Mouse Model of Alzheimer's Disease by Up-Regulating Insulin Degrading Enzyme and Inhibiting Aβ Accumulation
CNS & Neurological Disorders - Drug Targets Topiramate in the New Generation of Drugs: Efficacy in the Treatment of Alcoholic Patients
Current Pharmaceutical Design Exploring Modifications in Fetal Telomere Programming in Mothers Exposed to Multiple Risk Factors
Current Women`s Health Reviews The Medical Functions of Probiotics and Their Role in Clinical Nutrition
Current Nutrition & Food Science The Effects of Medications Used for the Management of Diabetes and Obesity on Postprandial Lipid Metabolism
Current Diabetes Reviews